S&P 500 Technology Sector SEC Filings — March 05, 2026

05-03-2026

Cumulus Media Inc. and its debtor affiliates have released a Disclosure Statement soliciting votes on a joint prepackaged Chapter 11 plan of reorganization in the U.S. Bankruptcy Court for the Southern District of Texas, with voting limited to Class 3 ABL Facility Claims, Class 4 2029 Secured Claims, and Class 5 Other Funded Debt Claims ahead of anticipated case commencement. Holders representing 72.05% of 2029 Debt Claims have committed to support the plan via a Restructuring Support Agreement, and the debtors' board strongly recommends acceptance by the April 7, 2026 voting deadline. The filing highlights ongoing challenges from a declining broadcast industry and liquidity pressures, with no quantified operational improvements noted.

• ·Record date for voting eligibility: February 23, 2026
• ·Voting deadline: 4:00 p.m. Central Time on April 7, 2026
• ·Debtors' service address: 780 Johnson Ferry Road, N.E., Suite 500, Atlanta, Georgia 30342
• ·Claims and noticing agent website: www.veritaglobal.net/cumulusmedia
• ·Anticipated bankruptcy court: Southern District of Texas, Houston Division

05-03-2026

On March 3, 2026, the Board of Directors of Acadia Pharmaceuticals Inc. appointed Jonathan M. Poole as a Class II director to fill a vacancy and as a member of the Audit Committee, effective immediately, with his term expiring at the 2027 Annual Meeting of Stockholders. Pursuant to the Non-Employee Director Compensation Policy, Mr. Poole will receive prorated annual cash retainers of $50,000 for Board service and $12,500 for Audit Committee service. He also received an initial equity grant under the 2024 Equity Incentive Plan with $200,000 target fair value and a prorated annual grant of $95,300 target fair value, with future annual grants set at $400,000 target fair value.

• ·Equity grants divided equally between nonstatutory stock options and restricted stock units; initial grant vests over three years, prorated grants vest over one year or at next annual meeting.
• ·No arrangements or understandings pursuant to which Mr. Poole was selected as director.
• ·No related person transactions required to be disclosed under Item 404(a) of Regulation S-K.

05-03-2026

Canadian Pacific Kansas City Limited announced via press release that its wholly owned subsidiary, Canadian Pacific Railway Company, is issuing $600M of 4.000% notes due 2029 and $600M of 5.500% notes due 2056, for a total of $1.2B. The offering is expected to close on March 6, 2026, subject to customary closing conditions.

• ·Filing dated March 5, 2026, reporting event of March 4, 2026
• ·Securities registered: Common Shares on NYSE (CP) and TSX (CP); Perpetual 4% Debentures on NYSE (CP40) and LSE (BC87)

05-03-2026

CrowdStrike reported FY26 total revenue of $4.81B, up 22% YoY from $3.95B, driven by 21% growth in subscription revenue to $4.56B and 29% in professional services to $0.25B, with ARR reaching $5.25B (24% YoY growth). However, the company posted a net loss attributable to CrowdStrike of $162.5M, wider than the $15.2M loss in FY25, as operating expenses surged 26% to $3.89B, outpacing revenue growth and leading to an operating loss of $293M (vs. $116M prior year). Gross margins remained flat at 75%, while sales & marketing, R&D, and G&A expenses rose 20%, 29%, and 39% YoY, respectively.

• ·Subscription represented 95% of total revenue in FY26, flat YoY.
• ·Professional services gross margin declined 1pp to 18% in FY26.
• ·Provision for income taxes was $34.2M in FY26, down from $71.1M in FY25.

05-03-2026

Altimmune reported cash, cash equivalents, and short-term investments of $274M as of December 31, 2025, up 107% YoY from $132M, strengthened further by $75M registered direct offering and $8M ATM in January 2026, providing runway for Phase 3 MASH trial initiation planned for 2026 and RECLAIM Phase 2 topline data in Q3 2026. Pemvidutide received FDA Breakthrough Therapy Designation for MASH based on positive IMPACT Phase 2b data showing fibrosis/inflammation improvements and additional weight loss. However, Q4 net loss widened 18% YoY to $27.4M driven by G&A expenses doubling to $10.5M, despite R&D decline; full-year net loss improved to $88.1M from $95.1M but revenues remained negligible at $41k.

• ·Jerry Durso appointed CEO, previously Chairman and Board member since Feb/Aug 2025.
• ·RECLAIM trial enrollment completed Nov 2025 ahead of schedule.
• ·RESTORE Phase 2 trial in ALD ongoing.
• ·FDA alignment on Phase 3 MASH design: 52-week, biopsy endpoints for accelerated approval.
• ·Common shares outstanding increased to 110.9M from 72.4M YoY.

05-03-2026

Aditxt, Inc. amended its Certificate of Incorporation to implement a 1-for-8 reverse stock split, effective March 6, 2026, at 4:01 p.m. Eastern Time, whereby every eight shares of old common stock will automatically convert into one share of new common stock. Fractional shares will be rounded up to a whole share, with the amendment duly approved by stockholders pursuant to Delaware General Corporation Law Section 242.

• ·Original Certificate of Incorporation filed with Delaware Secretary of State on September 28, 2017.
• ·Amendment inserts new Subsection (e) into ARTICLE IV, SECTION I.

05-03-2026

C2 Blockchain, Inc. filed an 8-K announcing the adoption of Amended and Restated Articles of Incorporation, approved by the Board of Directors and a majority of voting shareholders on March 4, 2026. The amendments authorize 1.52B total shares (1.5B Common Stock and 20M Preferred Stock, with 5M designated as Series A Preferred Stock offering 100 votes per share and convertible into 100 Common shares). No financial impacts or operational changes are disclosed; provisions include cumulative voting, indemnification, and transactions with interested directors.

• ·Series A Preferred Stock has liquidation preference equal to par value, then participates on as-converted basis.
• ·Cumulative voting enabled for director elections upon notice.
• ·Resident agent: Registered Agents Inc., 401 Ryland Street, Suite 200-A, Reno, NV 89502.

05-03-2026

NCS Multistage Holdings, Inc. reported total revenues of $183.6M for the year ended December 31, 2025, up 13.0% YoY from $162.6M, driven by strong U.S. growth of 33.5% but tempered by modest 4.7% growth in Canada. Net income rose 219.9% to $26.0M, boosted by a $9.2M tax benefit, while operating income increased 143.7% to $10.5M; however, services gross margin declined to 45.0% from 48.7%, and other countries services revenues fell 31.1% YoY.

• ·Net cash provided by operating activities increased to $22.2M in 2025 from $12.7M in 2024.
• ·U.S. services revenues surged 87.8% YoY to $18.0M.
• ·Product sales revenues grew 13.1% YoY to $127.9M, with Other Countries up 126.1%.
• ·Provision for litigation of $0.9M in 2025.
• ·Filing date: March 05, 2026 for year ended December 31, 2025.

05-03-2026

Evommune, Inc. (EVMN) reported FY2025 revenue growth of 86% YoY to $13M from $7M, primarily from license revenue, while completing an IPO with $157M net proceeds and converting all convertible preferred stock, boosting total assets to $225M and cash equivalents to $44.1M. However, operating expenses increased 22% YoY to $94.1M driven by 15% higher R&D ($74M) and 57% higher G&A ($20M), resulting in a widened net loss of $68.9M (up 3% YoY) and increased operating cash use to $76.4M. EVO301 R&D expenses declined sharply to $7.1M from $19.7M, while EVO756 R&D rose to $35.2M.

• ·Convertible preferred stock fully converted to common stock upon IPO, eliminating $257M non-cash liability.
• ·Stockholders' equity swung from ($144.2M) deficit in 2024 to $205.6M surplus in 2025.
• ·Property and equipment, net declined to $0.99M from $1.33M.
• ·Weighted average shares outstanding increased to 6.14M from 1.51M, reducing basic/diluted loss per share to ($11.22) from ($45.29).

05-03-2026

Amalgamated Financial Corp. (AMAL) reported total assets of $8.5B as of December 31, 2025, up from $8.3B in 2024, with net interest income growing 5.4% YoY to $297.8M on higher loan volumes (+$25.2M interest income) and total interest income up 5.2% to $422.2M at a 5.09% yield. However, non-interest income declined 6.9% YoY to $30.9M amid losses on securities sales and equity investments, while non-interest expenses rose 7.9% to $172.2M driven by higher compensation, professional fees, and technology costs; nonperforming assets also edged up slightly to $28.7M or 0.32% of assets.

• ·Average total loans grew to $4,720M in 2025 from $4,479M in 2024 (+5.4% YoY).
• ·Nonaccrual loans in commercial portfolio rose to $22.1M from $16.0M YoY.
• ·Allowance for credit losses on loans to total loans declined to 1.16% from 1.29% YoY.
• ·Service charges on deposit accounts dropped sharply to $17.5M from $32.2M YoY.

05-03-2026

Iridium Communications Inc. declared a cash dividend of $0.15 per share on its common stock, payable on March 31, 2026, to stockholders of record as of March 16, 2026. The Board of Directors approved the dividend on March 5, 2026. No comparative financial metrics or prior period data were disclosed.

• ·Filing submitted pursuant to Item 7.01 Regulation FD Disclosure.

05-03-2026

Entravision Communications Corp reported consolidated net revenue of $447.6M for the year ended December 31, 2025, up 23% YoY from $365.0M, driven by explosive 90% growth in Advertising Technology & Services to $270.9M; however, Media revenue declined 20% to $176.7M and direct operating expenses for that segment were nearly flat at $109.6M. Operating loss widened 60% to $83.4M from $52.0M, impacted by a $55.4M impairment charge, $25.2M loss on lease abandonment, and $2.8M restructuring costs, resulting in a net loss of $79.2M that improved from $148.9M in 2024 but remained negative with EPS of $(0.87). Cash and equivalents fell to $59.4M from $95.9M, total assets decreased to $387.5M, and stockholders' equity dropped to $55.4M from $146.0M.

• ·Cash flow from operating activities $10.6M in 2025, down from $74.7M in 2024.
• ·Capital expenditures $6.8M in 2025 vs $7.5M in 2024.
• ·Dividends declared $0.20 per common share in 2025, unchanged from prior years.
• ·Basic and diluted EPS $(0.87) in 2025 vs $(1.66) in 2024.
• ·Net cash used in financing activities $41.0M in 2025.

05-03-2026

Weave Communications, Inc. reported revenue growth of 17% YoY to $239M for the year ended December 31, 2025, from $204M in 2024, primarily driven by subscription and payment processing revenue which rose 17% to $229M. However, net loss was nearly flat at $28.1M versus $28.3M prior year, operating expenses increased 14% to $203M, and onboarding revenue declined 2% to $3.5M while gross margins remained deeply negative in onboarding (-153%) and phone hardware (-9%) segments. Total gross margin improved slightly to 72% from 71%.

• ·Stock-based compensation expense remained flat at $32.1M in 2025 vs. $32.2M in 2024.
• ·Incurrence of $1.7M in acquisition transaction costs and $0.9M in amortization of acquisition-related intangibles in 2025 (none in 2024).

05-03-2026

Net interest income rose $4.7M YoY to $51.2M for 2025, with net interest margin expanding to 3.12% from 2.73%, driven by favorable rates despite lower volumes. However, average loans declined to $1.35B from $1.43B, total interest income fell $2.0M to $87.6M, and nonperforming assets increased to $16.7M from $14.3M. Non-interest income grew 10.25% to $11.1M supported by gains on loan sales (+32%), while non-interest expenses edged up 1.49% to $42.9M.

• ·Capital ratios remain strong: Total capital 14.6% (2025) vs 15.6% (2024), all well above well-capitalized thresholds.
• ·CRE portfolio: $443M Non-Owner Occupied, $240M Owner-Occupied, with criticized loans at 1.4%-7.9% of segments.
• ·Net loan recoveries of $58k in 2025 vs net charge-offs of $100k in 2024; NCOs (annualized) 0.00% vs (0.01)%.

05-03-2026

Genco Shipping & Trading Limited executed a Sixth Amendment to its August 2021 Credit Agreement on February 27, 2026, establishing $80M in Incremental Revolving Commitments (2026 Upsize Revolving Commitments) to finance the acquisition of two 5-8 year old vessels: Genco Stars and Stripes and Genco Valkyrie (2026 Accordion Vessels). Consenting Lenders approved increasing the appraisal value threshold from 50% to 53.7% solely for these vessels, accepting pre-delivered appraisals from Fearnleys (Jan 20, 2026) and Clarksons (Jan 28, 2026). No declines or flat metrics reported in this financing update.

• ·Credit Agreement originally dated August 3, 2021; prior amendments on November 8, 2022; May 30, 2023; October 16, 2023; November 29, 2023; July 10, 2025
• ·Vessel appraisals dated January 20, 2026 (Fearnleys) and January 28, 2026 (Clarksons)

05-03-2026

Apple iSports Group, Inc. (AAPI) signed a Joint Venture Agreement with AiC Enterprises LLC (AiC) on February 28, 2026, to jointly supply a gaming products platform and technical services to B2B and B2C clients, while licensing the 'apple-i' brand for promotion in the gaming ecosystem. The agreement, approved by both boards, positions the companies to expand in online gambling services, led by AiC's CEO Michael Cho and supported by Apple iSports' management expertise under CEO Joe Martinez. No financial terms or performance metrics were disclosed.

• ·Agreement executed with legal effect on February 28, 2026 (Asia-Pacific time)
• ·AiC's infrastructure includes UX & Conversion Engineering, Secure Payment Rails, and Aggregator Ecosystem
• ·Websites: https://appleicasino.com, https://appleisports.com, https://corporate.appleisports.com

05-03-2026

Adial Pharmaceuticals reported a reduced net loss of $7.98M for the year ended December 31, 2025, compared to $13.20M in 2024, primarily due to lower R&D expenses ($2.62M, down 19% YoY) and absence of $4.46M inducement expense. However, G&A expenses rose slightly by 2% to $5.18M, total operating expenses declined modestly to $7.80M, and significant share dilution occurred with common shares outstanding increasing over 4x to 1.11M. Cash and equivalents grew 57% to $5.88M, bolstered by $8.47M in financing activities, though operating cash use remained high at $6.49M.

• ·Total assets increased to $6.67M as of Dec 31 2025 from $5.04M as of Dec 31 2024.
• ·Equity method investment declined to $0.49M from $0.98M.
• ·Net cash used in operating activities improved slightly to $6.49M from $6.92M.
• ·Weighted average shares outstanding increased to 668,630 from 194,059; loss per share improved to $(11.93) from $(68.01).

05-03-2026

Community Health Systems, Inc. (NYSE: CYH) announced a definitive agreement for a subsidiary to sell substantially all assets of four Arkansas hospitals (Northwest Medical Center – Bentonville (128 beds), Northwest Medical Center – Springdale (222 beds), Northwest Medical Center – Willow Creek Women’s Hospital (64 beds), and Siloam Springs Regional Hospital (73 beds), plus associated outpatient centers and practices) to Freeman Health System for $112 million, subject to adjustments for net working capital and finance leases. The transaction is expected to close in Q2 2026, subject to regulatory approvals and customary conditions. These hospitals were among potential divestitures referenced in CYH's Q4 2025 earnings call.

• ·CYH operates in 34 distinct markets across 13 states with headquarters in Franklin, Tennessee.
• ·Leerink Partners acting as exclusive financial advisor to CYH.